PHAT (Phathom Pharmaceuticals) Tax Rate % : 0.00% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Phathom Pharmaceuticals's Tax Expense for the three months ended in Sep. 2024 was $0.00 Mil. Phathom Pharmaceuticals's Pre-Tax Income for the three months ended in Sep. 2024 was $-85.58 Mil. Therefore, Phathom Pharmaceuticals's Tax Rate % for the quarter that ended in Sep. 2024 was 0.00%.

Phathom Pharmaceuticals Tax Rate % Historical Data

The historical data trend for Phathom Pharmaceuticals's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals Tax Rate % Chart

Phathom Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Rate %

Get a 7-Day Free Trial

Phathom Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Rate %	Get a 7-Day Free Trial															-	-	-	-	-

Phathom Pharmaceuticals Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Phathom Pharmaceuticals's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2023 )	/	Pre-Tax Income (A: Dec. 2023 )
	=	0	/	-201.592
	=	0.00 %

Phathom Pharmaceuticals's Tax Rate % for the quarter that ended in Sep. 2024 is calculated as

Tax Rate %	=	Tax Expense (Q: Sep. 2024 )	/	Pre-Tax Income (Q: Sep. 2024 )
	=	0	/	-85.577
	=	0.00 %

Phathom Pharmaceuticals Tax Rate % Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Phathom Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932

Website

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Executives

Azmi Nabulsi	officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Molly Henderson	officer: CFO and CBO	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Asit Parikh	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frank Karbe	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David A Socks	director, officer: President, CEO, Treas. & Sec.	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo	officer: VP, Chief Accounting Officer	C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse	director	5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola	director	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116